Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CVM logo CVM
Upturn stock ratingUpturn stock rating
CVM logo

CEL-SCI Corp (CVM)

Upturn stock ratingUpturn stock rating
$0.32
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/03/2025: CVM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -35.36%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 44.71M USD
Price to earnings Ratio -
1Y Target Price 7.73
Price to earnings Ratio -
1Y Target Price 7.73
Volume (30-day avg) 1039104
Beta 0.69
52 Weeks Range 0.22 - 2.39
Updated Date 02/14/2025
52 Weeks Range 0.22 - 2.39
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.52

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -61.41%
Return on Equity (TTM) -250.2%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 26552530
Price to Sales(TTM) 11797.42
Enterprise Value 26552530
Price to Sales(TTM) 11797.42
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.71
Shares Outstanding 63807100
Shares Floating 59687173
Shares Outstanding 63807100
Shares Floating 59687173
Percent Insiders 2.92
Percent Institutions 10.46

Analyst Ratings

Rating 4.5
Target Price 7.73
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CEL-SCI Corp

stock logo

Company Overview

History and Background

CEL-SCI Corp, founded in 1983, is a biotechnology company focused on cancer immunotherapy. It primarily develops investigational immunotherapy treatments for cancer. The company's history is centered around the development and clinical trials of its lead product, Multikine.

Core Business Areas

  • Immunotherapy Development: Focused on developing and commercializing immunotherapies for the treatment of cancer, primarily using its Multikine technology platform. This includes research, clinical trials, and regulatory submissions.

Leadership and Structure

CEL-SCI Corp's leadership includes Geert Kersten as CEO. The company operates with a structure typical of biotechnology firms, with departments focusing on research, clinical development, regulatory affairs, and finance.

Top Products and Market Share

Key Offerings

  • Multikine (Leukocyte Interleukin, Injection): Multikine is CEL-SCI Corp's lead investigational immunotherapy for the treatment of head and neck cancer. It has completed Phase 3 clinical trials. As an investigational product, it currently has no market share. Competitors include companies developing other head and neck cancer treatments such as Merck (Keytruda), Bristol Myers Squibb (Opdivo) and Erbitux.

Market Dynamics

Industry Overview

The biotechnology industry, specifically cancer immunotherapy, is highly competitive and rapidly evolving. There's growing interest in treatments that harness the body's immune system to fight cancer.

Positioning

CEL-SCI Corp is positioned as a company developing a novel immunotherapy for head and neck cancer. Its competitive advantage hinges on the success and differentiation of Multikine.

Total Addressable Market (TAM)

The global head and neck cancer therapeutics market is expected to reach billions of USD. CEL-SCI Corp's potential positioning within this TAM depends on Multikine's approval and adoption.

Upturn SWOT Analysis

Strengths

  • Novel immunotherapy approach
  • Completed Phase 3 clinical trials
  • Experienced management team

Weaknesses

  • Single product focus
  • Dependence on regulatory approval
  • History of operating losses

Opportunities

  • Potential for regulatory approval of Multikine
  • Expansion into other cancer indications
  • Partnerships with larger pharmaceutical companies

Threats

  • Failure to obtain regulatory approval
  • Competition from established cancer therapies
  • Clinical trial risks

Competitors and Market Share

Key Competitors

  • MRK
  • BMY
  • LLY
  • AZN

Competitive Landscape

CEL-SCI Corp faces intense competition from established pharmaceutical companies with approved cancer therapies. Its advantage depends on demonstrating superior efficacy and safety of Multikine.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: CEL-SCI Corp's historical growth has been characterized by research and development progress rather than revenue generation.

Future Projections: Future projections depend heavily on the regulatory approval and commercialization of Multikine. Analyst estimates vary significantly, reflecting the uncertainty surrounding the company's prospects.

Recent Initiatives: Recent strategic initiatives include focusing on regulatory submissions for Multikine and exploring potential partnerships.

Summary

CEL-SCI Corp is a high-risk, high-reward biotechnology company focused on developing Multikine, an immunotherapy for head and neck cancer. Its strength lies in its novel approach and completed Phase 3 trials, but it faces significant challenges related to regulatory approval and competition. The company's future hinges on the success of Multikine and its ability to secure partnerships and funding.

Similar Companies

  • MRK
  • BMY
  • AZN
  • PFE

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry News
  • Company Website

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CEL-SCI Corp

Exchange NYSE MKT
Headquaters Vienna, VA, United States
IPO Launch date 1987-01-01
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​